ADULT ORAL Updated: April 4, 2023

Regimen Reference Order - LYMP - zanubrutinib

ARIA: LYMP - [zanubrutinib]

Planned Course: Once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)

Indication for Use: Waldenström's Macroglobulinemia

Proceed with treatment if:

ANC equal to or greater than 0.75 x $10^9/L$ AND Platelets equal to or greater than 50 x $10^9/L$

Contact Hematologist if parameters not met

nubrutinib 320 mg* Orally once daily with or without food Swallow whole (Self-administered at home)	Dose	CCMB Administration Guideline
(Self-administered at home)	320 mg*	Orally once daily with or without food
		Swallow whole
		(Self-administered at home)
Alternate dosing schedule of 160 mg twice daily may be used at the prescriber's discretion	nedule of 160 mg twice da	ily may be used at the prescriber's discretion
nubrutinib (Brukinsa®) available dosage strength: 80 mg capsule	sa®) available dosage stro oxic, Hazardous	ength: 80 mg capsule
		320 mg* nedule of 160 mg twice da sa®) available dosage stro

REQUIRED MONITORING

Baseline

- Hepatitis B serology
- EKG

Throughout treatment

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders
 - o Every 2 to 4 weeks for the first 6 months, then
 - Every 12 weeks and as clinically indicated
- Monitor blood pressure and heart rate for tachycardia and irregular rhythm at every clinic visit
- · At physician's discretion, EKG to assess for atrial fibrillation if tachycardia or irregular rhythm present

Recommended Support Medications				
Drug	Drug Dose CCMB Administration Guideline			
None required				

INSTRUCTIONS FOR PATIENT

- Patients should report signs and symptoms of bleeding (i.e. excess bruising), palpitations, syncope and skin changes
- Patients should use necessary sun protection due to a potential increased risk of skin cancer
- When zanubrutinib is prescribed twice daily, doses of zanubrutinib should be separated by approximately 12 hours
- zanubrutinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- · Reinforce applicable safe handling precautions of medications, blood, and body fluids while on zanubrutinib



ADULT ORAL LYMP – zanubrutinib

ADDITIONAL INFORMATION

• Hematologist should be consulted regarding dosing of zanubrutinib pre- and post-surgery for patients undergoing a surgical procedure, including dental surgery, due to risk of bleeding regardless of platelet count

